Clinical Trials Logo

Cold Agglutinin Disease clinical trials

View clinical trials related to Cold Agglutinin Disease.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT05132127 Completed - Clinical trials for Cold Agglutinin Disease

Sutimlimab (BIVV009) for the Adult Participants With Cold Agglutinin Disease (CAD) Who Have Completed Phase 3 Studies (CARDINAL or CADENZA) in Japan

Start date: November 11, 2021
Phase: Phase 3
Study type: Interventional

This was a multi-center, single treatment-group, open-label study to provide sutimlimab to the adult participants with cold agglutinin disease (CAD) who had completed the CARDINAL (NCT number: NCT03347396) or CADENZA (NCT number: NCT03347422) studies and benefitted from sutimlimab treatment in Japan. • Study and treatment duration: the period between the participant's completion of the CARDINAL and CADENZA studies and sutimlimab or other appropriate CAD therapy becoming commercially available to participants in Japan.

NCT ID: NCT03347422 Completed - Clinical trials for Cold Agglutinin Disease

A Study to Assess the Efficacy and Safety of BIVV009 (Sutimlimab) in Participants With Primary Cold Agglutinin Disease Without A Recent History of Blood Transfusion

Cadenza
Start date: March 17, 2018
Phase: Phase 3
Study type: Interventional

The purpose of Part A was to determine whether sutimlimab administration resulted in a greater than or equal to (>=)1.5 grams per deciliter (g/dL) increase in hemoglobin (Hgb) level and avoidance of transfusion in participants with primary cold agglutinin disease (CAD) without a recent history of blood transfusion. The purpose of Part B was to evaluate the long-term safety and tolerability of sutimlimab in participants with primary CAD.

NCT ID: NCT03226678 Completed - Clinical trials for Warm Autoimmune Hemolytic Anemia

Study to Assess the Safety, Tolerability, Efficacy and PK of APL-2 in Patients With Warm Type Autoimmune Hemolytic Anemia (wAIHA) or Cold Agglutinin Disease (CAD)

Start date: August 31, 2017
Phase: Phase 2
Study type: Interventional

This study is to assess the safety, tolerability, preliminary efficacy, and pharmacokinetics of APL-2 in subjects with warm Autoimmune Hemolytic Anemia (wAIHA) or Cold Agglutinin Disease (CAD).

NCT ID: NCT02689986 Completed - Clinical trials for Autoimmune Hemolytic Anemia

Bendamustine and Rituximab Combination Therapy for Cold Agglutinin Disease

CAD5
Start date: January 2013
Phase: Phase 2
Study type: Interventional

Prospective, non-randomized multicenter study on the safety and efficacy of combination therapy with bendamustine and rituximab for chronic cold agglutinin disease.

NCT ID: NCT01303952 Completed - Clinical trials for Cold Agglutinin Disease

Therapy of Chronic Cold Agglutinin Disease With Eculizumab

DECADE
Start date: January 2011
Phase: Phase 2
Study type: Interventional

Evaluation of the efficacy and safety of eculizumab in symptomatic or transfusion-dependent patients with untreated or refractory hemolytic cold agglutinin disease(CAD)

NCT ID: NCT00960713 Completed - Pemphigus Clinical Trials

The RITAI Cohort: An Observational Study on Rituximab Off-label Use for Auto-immune Disorders

RITAI
Start date: June 2009
Phase: N/A
Study type: Observational

The primary purpose of the study is to describe by a prospective observational study the serious adverse events occurring in patients treated off-label by rituximab for various auto-immune diseases.

NCT ID: NCT00373594 Completed - Clinical trials for Cold Agglutinin Disease

Therapy for Chronic Cold Agglutinin Disease

Start date: June 2005
Phase: Phase 2
Study type: Interventional

Chronic cold agglutinin disease (CAD) is a type of autoimmune hemolytic anemia (anemia due to destruction of red blood cells by abnormal antibodies). Almost all patients also suffer from cold-induced disturbances of blood circulation. The purpose of this study is to assess the efficacy and safety of combination therapy with rituximab (an antibody against B lymphocytes) and fludarabine (a cytotoxic drug) for CAD. Another aim is to try to assess whether these agents in combination are better than single agent therapy with rituximab.